Analysts’ New Coverage for July 23rd (AGMB, BXSL, CMTL, CYAB, GWRE, IRTC, LAUR, NPCE, PAGS, PCOR)

Analysts’ new coverage for Thursday, July 23rd:

B. Riley Financial, Inc. started coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB). The firm issued a buy rating and a $34.00 price target on the stock.

Oppenheimer Holdings, Inc. assumed coverage on shares of Blackstone Secured Lending Fund (NYSE:BXSL). They issued a market perform rating and a $25.00 target price on the stock.

Northcoast Research assumed coverage on shares of Comtech Telecommunications (NASDAQ:CMTL). They issued a buy rating and a $2.50 price target on the stock.

Maxim Group began coverage on shares of Cyabra (NASDAQ:CYAB). Maxim Group issued a buy rating and a $1.00 target price on the stock.

Guggenheim began coverage on shares of Guidewire Software (NYSE:GWRE). They issued a buy rating and a $180.00 target price on the stock.

Stephens initiated coverage on shares of iRhythm Technologies (NASDAQ:IRTC). Stephens issued an overweight rating and a $160.00 price target on the stock.

Barrington Research initiated coverage on shares of Laureate Education (NASDAQ:LAUR). Barrington Research issued an outperform rating and a $45.00 target price on the stock.

Mizuho initiated coverage on shares of NeuroPace (NASDAQ:NPCE). Mizuho issued an outperform rating and a $22.00 target price on the stock.

Jefferies Financial Group Inc. started coverage on shares of PagSeguro Digital (NYSE:PAGS). Jefferies Financial Group Inc. issued a hold rating and a $10.40 price target on the stock.

Guggenheim initiated coverage on shares of Procore Technologies (NYSE:PCOR). The firm issued a buy rating and a $68.00 price target on the stock.

Piper Sandler started coverage on shares of Shell (NYSE:SHEL). The firm issued a neutral rating and a $88.00 price target on the stock.

Guggenheim started coverage on shares of Veeva Systems (NYSE:VEEV). Guggenheim issued a buy rating and a $232.00 target price on the stock.

Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL). They issued a buy rating and a $11.00 target price on the stock.